SCHEDULE 13G/A 0001465302 XXXXXXXX LIVE 1 Common Stock, par value $0.005 per share 06/30/2025 0000748592 Ernexa Therapeutics Inc. 114082308 1035 Cambridge Street Suite 18A Cambridge MA 02141 Rule 13d-1(c) Shameek Konar X1 0.00 558531.00 0.00 558531.00 558531.00 N 7.12 IN Rows 6, 8 and 9 consist of (i) 547,668 shares of the Common Stock of Ernexa Therapeutics Inc. (formerly Eterna Therapeutics Inc., the "Issuer") owned by Regolith Capital Investments LP ("Regolith") and (ii) 10,863 shares of common stock owned by Mr. Konar. Mr. Konar and Victoria Konar are the general partners of Regolith and Mr. Konar disclaims beneficial ownership of the securities held by Regolith except to the extent of his pecuniary interest therein. Percentage of ownership in Row 11 is based on an aggregate of 7,848,889 shares of Common Stock outstanding as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 7, 2025. This Amendment No. 1 amends the Schedule 13G filed by the Reporting Person named therein on May 15, 2025. Victoria Konar X1 0.00 558531.00 0.00 558531.00 558531.00 N 7.12 IN Rows 6, 8 and 9 consist of (i) 547,668 shares of the Common Stock of Ernexa Therapeutics Inc. (formerly Eterna Therapeutics Inc., the "Issuer") owned by Regolith Capital Investments LP ("Regolith") and (ii) 10,863 shares of common stock owned by Ms. Konar's spouse, Shameek Konar. Ms. Konar and Shameek Konar are the general partners of Regolith and Ms. Konar disclaims beneficial ownership of the securities held by Regolith except to the extent of her pecuniary interest therein. Percentage of ownership in Row 11 is based on an aggregate of 7,848,889 shares of Common Stock outstanding as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 7, 2025. This Amendment No. 1 amends the Schedule 13G filed by the Reporting Person named therein on May 15, 2025. Regolith Capital Investments LP TX 0.00 547668.00 0.00 547668.00 547668.00 N 6.98 PN Regolith is a Texas limited liability partnership. Shameek Konar and Victoria Konar are the general partners of Regolith. Row 11 is calculated based on 7,848,889 shares of the Common Stock of the Issuer outstanding as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 7, 2025. This Amendment No. 1 amends the Schedule 13G filed by the Reporting Person named therein on May 15, 2025. Ernexa Therapeutics Inc. 1035 Cambridge Street, Suite 18A, Cambridge, MA 02141 This statement is filed by the following entity and individuals (collectively referred to as the "Reporting Persons") Shameek Konar Victoria Konar Regolith Capital Investments LP Shameek Konar and Victora Konar are the general partners of Regolith Capital Investments LP, and as a result, may be deemed to share voting and dispositive power with respect to the securities held by Regolith Capital Investments LP. Regolith Capital Investments LP, Mr. Konar and Ms. Konar have entered into a Joint Filing Agreement, a copy of which is filed as Exhibit 99.1 to the initial Schedule 13G filed on May 15, 2025 and is hereby incorporated by reference, pursuant to which they have agreed to file this Amendment jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended. The address for each of the Reporting Persons is 10608 Stoppard View Way, Knoxville, TN 37922. See Row 4 of each Reporting Person's cover page to this Schedule 13G. Y See Row 9 of the Reporting Person's cover page to this Schedule 13G. See Row 11 of the Reporting Person's cover page to this Schedule 13G. See Row 5 of the Reporting Person's cover page to this Schedule 13G. See Row 6 of the Reporting Person's cover page to this Schedule 13G. See Row 7 of the Reporting Person's cover page to this Schedule 13G. See Row 8 of the Reporting Person's cover page to this Schedule 13G. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Shameek Konar /s/ Shameek Konar 12/16/2025 Victoria Konar /s/ Victoria Konar 12/16/2025 Regolith Capital Investments LP /s/ Shameek Konar 12/16/2025